¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Fab' fragment"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • antigen binding fragment
    Ç׿ø°áÇÕºÎÀ§
  • acentric fragment
    ¹«Áß½ÉÀýÁ¶°¢, ¿°»öü´ÜÆí, ¹«Áß½Éü´ÜÆí
  • bone fragment
    »ÄÁ¶°¢, °ñÆí
  • Fc fragment
    FcºÐÀý
  • fallen fragment sign
    ³«ÇÏÆÄÆí¡ÈÄ
  • fracture fragment
    °ñÀýÁ¶°¢, °ñÀýÀýÆí
  • fragment
    Á¶°¢, Æí
  • restriction fragment length polymorphism
    Á¦ÇÑÀýÆí±æÀÌ´ÙÇüÅÂ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • fragment
    Á¶°¢
  • bone fragment
    »ÄÁ¶°¢
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 7 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • acentric fragment
    ¹«Áß½ÉÀýÁ¶°¢, ¿°»öü´ÜÆí, ¹«Áß½Éü´ÜÆí
  • antigen binding fragment
    Ç׿ø°áÇÕºÎÀ§
  • bone fragment
    »ÀÁ¶°¢, °ñÆí
  • fragment
    Á¶°¢
  • fallen fragment sign
    ³«ÇÏÆÄÆí¡ÈÄ
  • fracture fragment
    °ñÀýÁ¶°¢, °ñÀýÀýÆí
  • restriction fragment length polymorphism
    Á¦ÇÑÀýÆí±æÀÌ´ÙÇü¼º
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 11 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Fab fragment
    Fab ºÐÀý.
  • Fab fragment
    Fab Á¶°¢.
  • Fab fragment
    Fab ºÐÀý
  • FAB =>French-american-British leukemia classification
    FAB ¹éÇ÷º´ºÐ·ù
  • Fab fragments
    Fab ºÐÀý(ÝÂï½)
  • F(ab) fragment
    F(ab)Á¶°¢
  • acentric fragment
    ¿°»öü´ÜÆí, ¹«Áß½Éü´ÜÆí
  • antigen binding fragment
    Ç׿ø°áÇÕºÎÀ§
  • fracture fragment
    °ñÀý Æí(Íéï¹ø¸).
  • fragment
    ¼¼Æí, ÆÄÆí(÷òø¸), ´ÜÆí(Ó¨ø¸), ºÐÀý, ÆíÀý, °ñÆí(Íéø¸).
  • fragment
    ÀýÆí, ºÐÀý, Á¶°¢
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 13 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • acentric fragment
    ¿°»öü´ÜÆí, ¹«Áß½Éü´ÜÆí
  • antigen binding fragment
    Ç׿ø°áÇÕºÎÀ§
  • bone fragment
    °ñÆí(Íéø¸), °ñ Á¶°¢.
  • detached fragment
    À¯¸®(°ñ)Æí(ë´ìÆÍéø¸).
  • fallen fragment sign
    ³«ÇÏ ÆÄÆí ¡ÈÄ
  • fracture fragment
    °ñÀý Æí(Íéï¹ø¸).
  • fragment
    ÀýÆí, ºÐÀý, Á¶°¢
  • fragment
    ¼¼Æí, ÆÄÆí(÷òø¸), ´ÜÆí(Ó¨ø¸), ºÐÀý, ÆíÀý, °ñÆí(Íéø¸).
  • restriction fragment length polymorphism
    Á¦ÇѼ¼Æí±æÀÌ´ÙÇü¼º(ð¤ùÚ¼¼Æí¡­Òýû¡à÷)
  • restriction fragment length polymorphism,in cystic fibrosis
    ³¶¼º¼¶À¯Áõ(ÀÇ)¡­(Ò¥àõàéë«ñø¡­)
  • restriction fragment length polymorphism analysis
    Á¦ÇÑÀý´Ü±æÀÌ´ÙÇüÁõºÐ¼®
  • restriction fragment length polymorphism=RFLP
    Á¦ÇÑÀýÆí±æÀ̴پ缺
  • urinary gonadotropin fragment/peptide
    ¿äÁß¼º¼±ÀÚ±ØÈ£¸£¸óºÐÀý/ÆéƼµå
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Fab' fragment
    Fab' Á¶°¢
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Fab fragment
    Fab Á¶°¢
  • FAB-MS
    (å²) fast atom bombardment mass spectrometry
  • antigen-binding fragment
    Ç׿ø°áÇÕ(ù÷ê«Ì¿ùê) Á¶°¢
  • crystallizable fragment
    "°áÁ¤(Ì¿ïÜ) Á¶°¢, (ÔÒ) fc fragment"
  • F(ab')2 fragment
    F(ab')2 Á¶°¢
  • Fc fragment
    Fc Á¶°¢
  • Fd fragment
    Fd Á¶°¢
  • Fd' fragment
    Fd' Á¶°¢
  • (F1+F2) fragment
    (F1 + F2) Á¶°¢
  • F1 fragment
    F1 Á¶°¢
  • F2 fragment
    F2 Á¶°¢
  • F3 fragment
    F3 Á¶°¢
  • fragment ion
    Á¶°¢ ÀÌ¿Â
  • fragment length mapping
    Á¶°¢ ±æÀÌ ÀÛµµ(íÂÓñ)
  • fragment map
    Á¶°¢ Áöµµ(ò¢Óñ)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • bone fragment
    °ñÆí
  • fragment
    ¼¼Æí, ÆÄÆí, ´ÜÆí, ºÐÀý, ÆíÀý, °ñÆí
  • gelfoam fragment
    Á©Æû Á¶°¢
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
FAB fast atom bombardment; formalin ammonium bromide; fragment, antigen-binding [of immunoglobulins]; Fr...
Fab fragment, antigen-binding [of immunoglobulins]
FAB classification French, American, British classification
RFLPs Restriction Fragment Length Polymorphisms; Á¦ÇÑÈ¿¼Ò´ÜÆíÀå´ÙÇü
UGF Urinary Gonadotropin Fragment
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
FAB Fast Atom Bombardment
FAB-MS Fast Atom Bombardment Mass Spectrometry
FAB MS Fast Atom Bombardment Mass Spectroscopy
FAB French American British
AFLP Amplified Fragment Length Polymorphism
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 12 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • Fab
    Ç׿ø °áÇÕ ºÐÀý
    IgGÀÇ
  • amino fragment
    ¾Æ¹Ì³ë ÀýÆí
  • antigen binding fragment
    Ç׿ø °áÇÕ ºÎÀ§
  • bone fragment
    °ñÆí
  • carboxy fragment
    ź¼Ò ÀýÆí
  • detached fragment
    À¯¸®Æí, À¯¸® °ñÆí
  • enkephalin fragment
    ¿£ÄÉÆÈ¸° ºÐÀý
  • fracture fragment
    °ñÀý Æí
  • fragment
    ºÐÀý, ¼¼Æí, ÆÄÆí, ´ÜÆí, ÆíÀý, °ñÆí
    Å« Àüü°¡ ÆÄ±«µÇ¾î Çü¼ºµÈ ¼ÒÆí.
  • multiple biologically active peptide fragment
    ´Ù¹ß¼º »ý¹°ÇÐÀû Ȱ¼º ÆéŸÀÌµå ºÐÀý
  • prodynorphin-derived fragment
    ÇÁ·Î´ÙÀ̳븣ÇÉ À¯·¡ ºÐÀý
  • root fragment
    Ä¡±Ù ÆÄÆí, Ä¡±Ù ÀýÆí
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
Fab fragment The antigen-binding fragment of an immunoglobulin molecule, consisting of both a light chain and part of a heavy chain.
Synonym: Fab piece.
(05 Mar 2000)
immunoglobulins, fab Antigen-binding fragments composed of one entire light chain and about half of one of the heavy chains, linked to each other by disulfide bonds. Fab contains the antigen binding site which is part of the variable region of the immunoglobulin molecule.
(12 Dec 1998)
Fab <immunology> Fragment of immunoglobulin prepared by papain treatment. Fab fragments (45 kD) consist of one light chain linked through a disulphide bond to a portion of the heavy chain and contain one antigen binding site. They can be considered as univalent antibodies.
(18 Nov 1997)
FAB classification <haematology> The classification of acute myeloid leukaemia on the basis of bone marrow and peripheral blood features.
M0: Acute myeloid leukaemia with minimal evidence of myeloid differentiation.
M1: Acute myeloblastic leukaemia.
M2: Acute myeloblastic leukaemia with differentiation.
M3: Acute promyelocytic leukaemia.
M4: Acute myelomonocytic leukaemia.
M5: Acute monocytic leukaemia.
M6: Acute erythroleukaemia.
M7: Acute megakaryocytic leukaemia.
Acronym: FAB
(07 Apr 1998)
Fab piece The antigen-binding fragment of an immunoglobulin molecule, consisting of both a light chain and part of a heavy chain.
Synonym: Fab piece.
(05 Mar 2000)
acentric fragment A fragment of a chromosome lacking a centromere and unable to attach to the mitotic spindle, therefore unable to take part in the division of a nucleus and randomly distributed in daughter cells.
Synonym: acentric fragment.
(05 Mar 2000)
amplified fragment length polymorphism <technique> Invented by KeyGene, a Dutch biotech company based in Wageningen, Holland. The technique is now merchandised under licence agreement by Perkin Elmer.
Selected markers are amplified in a PCR, which makes amplified fragment length polymorphism an easy and fast tool for strain identification in agriculture, botany, microbiology and animal breeding.
Acronym: AFLP
(05 Feb 1998)
Brimacombe fragment A ribonucleoprotein fragment obtained by mild ribonuclease treatment of ribosomes.
(05 Mar 2000)
butterfly fragment A broad triangular fragment that is commonly present in comminuted fractures of the diaphysis.
(05 Mar 2000)
restriction fragment <molecular biology> The fragments of DNA generated by digesting DNA with a specific restriction endonuclease. Each of the fragments ends in a site recognised by that specific enzyme.
(10 Mar 1998)
restriction fragment length polymorphism <molecular biology, technique> A method that allows familial relationships to be established by comparing the characteristic polymorphic patterns that are obtained when certain regions of genomic DNA are amplified (typically by PCR) and cut with certain restriction enzymes.
The variation in the length of DNA fragments produced by a restriction endonuclease that cuts at a polymorphic locus. Such variations are generated by mutations that create or abolish recognition sites for these enzymes.
This is a key tool in DNA fingerprinting, reflecting the existence of different alleles in the individual. Restriction fragment length polymorphism mapping is also used in plant breeding to see if a key trait such as disease resistance is inherited.
In principle, an individual can be identified unambiquously by restriction fragment length polymorphism hence the use of restriction fragment length polymorphism in forensic analysis of blood, hair or semen).
Similarly, if a polymorphism can be identified close to the locus of a genetic defect, it provides a valuable marker for tracing the inheritance of the defect.
Synonym: DNA fingerprinting.
Acronym: RFLP
(12 Jan 1998)
Okazaki fragment A relatively short (100-1000 bp) fragment of DNA that is later joined by DNA ligase to allow for 3' &rarr; 5' overall chain growth during replication.
(05 Mar 2000)
one-carbon fragment The formyl group or the methyl group that takes part in transformylation or transmethylation reactions; by means of these reactions, a group containing a single carbon atom is added to a compound being biosynthesised, adding a methyl group (as in thymidine formation), adding a hydroxymethyl group (as in serine biosynthesis), or closing a ring (as in purine formation).
(05 Mar 2000)
two-carbon fragment The acetyl group (CH3CO-) that takes part in transacetylation reactions with coenzyme A as carrier; commonly referred to as acetate or acetic acid, from which it is derived.
(05 Mar 2000)
f2 fragment <immunology> A fragment of an antibody protein which includes the antigen-binding portions but not the Fc section. They can be produced by treating whole antibodies with proteases that will specifically cleave off the Fc section.
(09 Oct 1997)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • fab
    =FABULOUS
  • fission fragment
    Çٺп­ÀÇ ÆÄÆí
  • fragment
    ÆÄÆí;´ÜÆí;¹Ì¿Ï¼º À¯°í;ºÎ¼­Áø Á¶°¢;»ê»êÀÌ ºÎ¼ö´Ù;»ê»ê Á¶°¢ÀÌ µÇ´Ù;ºÎ¼­Áö´Ù
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á